Amplia Therapeutics (ASX:ATX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Amplia Therapeutics (ASX:ATX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Amplia Therapeutics Shareholder Webinar
Initial Director's Interest Notice - Brett Carter
Amplia Announces Appointment of Brett Carter to Board
Annual General Meeting to be held Friday 28 August 2026
Amplia Announces Changes to Board's Leadership Roles
Notice of Initial Substantial Holding from SOL
Becoming a substantial holder from PCG
Appendix 4G - Key to Corporate Governance Disclosures
Corporate Governance Statement 2026
Preliminary Final Report and Annual Report YE 31 March 2026
Amplia Therapeutics advances pancreatic cancer drug narmafotinib with positive trial data and $27.5M capital raise
Amplia Launches First Stage of Pivotal Narmafotinib Trial
Amplia Therapeutics launches Phase 2b trial of narmafotinib for pancreatic cancer with new daily dosing
Notice under Section 708A(5)(e) of the Corporations Act
Application for quotation of securities - ATX
Amplia and ANZGOG announce Ovarian Cancer Study
Amplia Therapeutics and ANZGOG launch ovarian cancer trial for narmafotinib
Quarterly Activities/Appendix 4C Cash Flow Report
Amplia Therapeutics reports positive ACCENT trial results, GMP production milestone, CFO appointment, and $27.9M cash at March 2026 quarter end
ACCENT Trial Mature Data Presented at AACR Conference